Drugs known as tyrosine kinase inhibitors (TKIs) that target the BCR::ABL1 protein (oral targeted therapy) are the conventional treatment of CML, representing a change of paradigm in the management of oncohematological patients. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.